第一阶段和第二阶段非小细胞肺癌的治疗选择
Georgia Hardavella1, Dimitrios E Magouliotis2, Roberto Chalela3
14th-9th Department of Respiratory Medicine, 'Sotiria' Athens' Chest Diseases Hospital, Athens, Greece.
Breathe (Sheffield, England)
|August 28, 2024
概括
本研究概述了非小细胞肺癌 (NSCLC) 的分期和治疗方法. 它详细介绍了基于癌症阶段和突变的手术切除,放射治疗,化疗和免疫治疗选择,以获得最佳的患者结果.
科学领域:
- 在瘤学瘤学.
- 放射学 放射学是一门学科.
- 医疗成像医学成像
背景情况:
- 精确的非小细胞肺癌 (NSCLC) 阶段确定对于有效的治疗计划至关重要.
- 包括胸部放射,计算机断层扫描 (CT) 和正子发射断层扫描 (PET) -CT在内的成像模式对于NSCLC分期至关重要.
- 瘤大小和淋巴结参与定义NSCLCI,II阶段及以上.
研究的目的:
- 为提供对非小细胞肺癌目前的分期标准的概述.
- 总结了NSCLC不同阶段的推治疗策略,包括手术,放射治疗和化疗选择.
- 突出新辅助和辅助疗法的作用,包括免疫疗法和向药物,以优化NSCLC患者的治疗结果.
主要方法:
- 审查用于NSCLC分期的诊断成像技术 (X射线,CT,PET-CT).
- 基于NSCLC瘤大小,淋巴结状况和分子突变的治疗指南的分析.
- 对各种治疗方式的证据评估:手术,立体体质放射疗法,化疗,免疫疗法和向治疗.
主要成果:
- 阶段IANSCLC (≤3厘米) 最好通过手术切除进行治疗,以叶片切除作为标准和亚叶片切除作为潜在的替代方案.
- 对于不可切除的IA阶段NSCLC,立体体辐射疗法提供了一个可行的治疗选择.
- 阶段IB至IIB的NSCLC受益于包括手术,化疗,免疫疗法和放射疗法在内的综合模式治疗,新辅助免疫疗法和化疗显示出有前途.
- 辅助性基化疗,布罗利祖马布和奥西默蒂尼布 (针对特定突变) 建议用于切除的NSCLCIIB-IIIA阶段.
- 随访通常包括每6个月一次CT扫描治疗后2-3年,然后过渡到每年一次扫描.
结论:
- 对NSCLC的治疗决定取决于阶段,包括瘤大小,结节状况和分子特征.
- 最少侵入性手术和固态体辐射疗法是早期NSCLC的关键选择.
- 多模式治疗策略,包括新辅助和辅助疗法,对于优化局部晚期NSCLC的结果至关重要.
- 使用免疫疗法和向治疗的个性化治疗方法在NSCLC管理中越来越重要.
- 标准化后续协议有助于在最终的NSCLC治疗后早期检测复发.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
01:27Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
162
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
162
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
149
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
149